Amneal reaffirms FY2022 guidance: revenue $2.15-2.25B, adj. EBITDA $500-520M

Amneal Pharmaceuticals, Inc.

Reaffirmed FY2022 net revenue guidance of $2.15B-$2.25B; no change from Nov 4, 2022.
Adjusted EBITDA forecast unchanged at $500M-$520M; adjusted diluted EPS $0.65-$0.70.
Operating cash flow guidance $200M-$225M; capex $65M-$75M; diluted shares ~305M.
Guidance includes 100% of AvKARE EBITDA; accounts for 35% non-controlling interest.
Opana ER antitrust litigation cash payments of ~$131M excluded from operating cash flow guidance.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amneal Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: revenue $2.15 billion - $2.25 billion, EPS $0.65 - $0.70. Guidance reaffirmed.

Period: the year ended December 31, 2022
Revenue: $2.15 billion - $2.25 billion
EPS: $0.65 - $0.70
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

In connection with a presentation to be made at an investor conference on January 10, 2023, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), reaffirms previously issued guidance with respect to the year ended December 31, 2022, which was previously issued on November 4, 2022 in connection with the Company’s third quarter 2022 results: Full Year 2022 Financial Guidance Net revenue $2.15 billion - $2.25 billion Adjusted EBITDA (1) $500 million - $520 million Adjusted diluted EPS (2) $0.65 - $0.70 Operating cash flow (3) $200 million - $225 million Capital expenditures $65 million - $75 million Weighted average diluted shares outstanding (4) Approximately 305 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-005141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.